Devin M Parker1, Sherry L Owens1, Niveditta Ramkumar1, Donald Likosky2, Anthony W DiScipio3, David J Malenka3, Todd A MacKenzie1, Jeremiah R Brown4. 1. The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Lebanon, New Hampshire. 2. Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan. 3. Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. 4. The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Lebanon, New Hampshire; Department of Epidemiology, Geisel School of Medicine, Lebanon, New Hampshire; Department of Biomedical Data Science, Geisel School of Medicine, Lebanon, New Hampshire. Electronic address: jbrown@dartmouth.edu.
Abstract
BACKGROUND: Galectin-3 (Gal-3) is a well-established biomarker of adverse clinical outcomes, but its prognostic value for long-term survival after cardiac surgery is not well understood. Elevated levels of Gal-3 have been found to be remarkably associated with higher risk of death in both acute decompensated and chronic heart failure populations. Its prognostic value for long-term survival after cardiac surgery is not known. METHODS: A sample of patients contributing to the Northern New England Cardiovascular Disease Study Group Cardiac Surgery Registry from 2004 to 2007 were enrolled in a prospective biomarker cohort (N = 1690). Preoperative Gal-3 levels were measured and categorized by quartile. We used Kaplan-Meier survival analysis and Cox regression models, adjusting for variables in The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategy probability calculator to evaluate the association between elevated Gal-3 levels and survival to 6 years. RESULTS: Preoperative Gal-3 levels ranged from 1.72 to 28.89 ng/mL (mean, 8.96 ng/mL; median, 8.06 ng/mL; interquartile range, 5.42-11.08 ng/mL). Crude survival decreased by increasing quartile. After adjustment, serum levels of Gal-3 in the highest quartile of the cohort were associated with significantly decreased survival compared with the lowest quartile (hazard ratio [HR] 2.22; 95% confidence interval [CI], 1.40-3.54; P = .001). No decrease in survival was found for the middle quartiles (HR 1.36; 95% CI, 0.87-2.12; P = .177). CONCLUSIONS: A substantial association was found between elevated preoperative Gal-3 levels and risk of mortality after isolated coronary artery bypass grafting surgery. An assessment of the relationship between preoperative serum biomarkers and long-term survival can be used for risk stratification or estimating postsurgical prognosis.
BACKGROUND:Galectin-3 (Gal-3) is a well-established biomarker of adverse clinical outcomes, but its prognostic value for long-term survival after cardiac surgery is not well understood. Elevated levels of Gal-3 have been found to be remarkably associated with higher risk of death in both acute decompensated and chronic heart failure populations. Its prognostic value for long-term survival after cardiac surgery is not known. METHODS: A sample of patients contributing to the Northern New England Cardiovascular Disease Study Group Cardiac Surgery Registry from 2004 to 2007 were enrolled in a prospective biomarker cohort (N = 1690). Preoperative Gal-3 levels were measured and categorized by quartile. We used Kaplan-Meier survival analysis and Cox regression models, adjusting for variables in The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategy probability calculator to evaluate the association between elevated Gal-3 levels and survival to 6 years. RESULTS: Preoperative Gal-3 levels ranged from 1.72 to 28.89 ng/mL (mean, 8.96 ng/mL; median, 8.06 ng/mL; interquartile range, 5.42-11.08 ng/mL). Crude survival decreased by increasing quartile. After adjustment, serum levels of Gal-3 in the highest quartile of the cohort were associated with significantly decreased survival compared with the lowest quartile (hazard ratio [HR] 2.22; 95% confidence interval [CI], 1.40-3.54; P = .001). No decrease in survival was found for the middle quartiles (HR 1.36; 95% CI, 0.87-2.12; P = .177). CONCLUSIONS: A substantial association was found between elevated preoperative Gal-3 levels and risk of mortality after isolated coronary artery bypass grafting surgery. An assessment of the relationship between preoperative serum biomarkers and long-term survival can be used for risk stratification or estimating postsurgical prognosis.
Authors: L David Hillis; Peter K Smith; Jeffrey L Anderson; John A Bittl; Charles R Bridges; John G Byrne; Joaquin E Cigarroa; Verdi J Disesa; Loren F Hiratzka; Adolph M Hutter; Michael E Jessen; Ellen C Keeley; Stephen J Lahey; Richard A Lange; Martin J London; Michael J Mack; Manesh R Patel; John D Puskas; Joseph F Sabik; Ola Selnes; David M Shahian; Jeffrey C Trost; Michael D Winniford Journal: Circulation Date: 2011-11-07 Impact factor: 29.690
Authors: James S Tweddell; Lynn A Sleeper; Richard G Ohye; Ismee A Williams; Lynn Mahony; Christian Pizarro; Victoria L Pemberton; Peter C Frommelt; Scott M Bradley; James F Cnota; Jennifer Hirsch; Paul M Kirshbom; Jennifer S Li; Nancy Pike; Michael Puchalski; Chitra Ravishankar; Jeffrey P Jacobs; Peter C Laussen; Brian W McCrindle Journal: J Thorac Cardiovasc Surg Date: 2012-02-15 Impact factor: 5.209
Authors: Antoni Bayes-Genis; Marta de Antonio; Joan Vila; Judith Peñafiel; Amparo Galán; Jaume Barallat; Elisabet Zamora; Agustin Urrutia; Josep Lupón Journal: J Am Coll Cardiol Date: 2013-09-24 Impact factor: 24.094
Authors: Umesh C Sharma; Saraswati Pokharel; Thomas J van Brakel; Jop H van Berlo; Jack P M Cleutjens; Blanche Schroen; Sabine André; Harry J G M Crijns; Hans-J Gabius; Jos Maessen; Yigal M Pinto Journal: Circulation Date: 2004-11-01 Impact factor: 29.690
Authors: Dirk J A Lok; Peter Van Der Meer; Pieta W Bruggink-André de la Porte; Erik Lipsic; Jan Van Wijngaarden; Hans L Hillege; Dirk J van Veldhuisen Journal: Clin Res Cardiol Date: 2010-02-04 Impact factor: 5.460
Authors: Hendrik Milting; Peter Ellinghaus; Michael Seewald; Hamdin Cakar; Birte Bohms; Astrid Kassner; Reiner Körfer; Martina Klein; Thomas Krahn; Lothar Kruska; Aly El Banayosy; Frank Kramer Journal: J Heart Lung Transplant Date: 2008-06 Impact factor: 10.247
Authors: Nisha Bansal; Ronit Katz; Stephen Seliger; Christopher DeFilippi; Mark J Sarnak; Joseph A Delaney; Robert Christenson; Ian H de Boer; Bryan Kestenbaum; Cassianne Robinson-Cohen; Joachim H Ix; Michael G Shlipak Journal: Am J Kidney Dis Date: 2016-01-29 Impact factor: 8.860
Authors: Jeremiah R Brown; Devin M Parker; Meagan E Stabler; Marshall L Jacobs; Jeffrey P Jacobs; Allen D Everett; Kevin W Lobdell; Moritz C Wyler von Ballmoos; Heather Thiessen-Philbrook; Chirag Parikh; Todd Mackenzie; Anthony DiScipio; David Malenka; Michael E Matheny; Alexander Turchin; Donald S Likosky Journal: J Card Surg Date: 2021-09-02 Impact factor: 1.778